The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Cancer Letters

• Publication date

  2008-12-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.canlet.2008.07.018PMID 18774637
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin.

  2008cited by this paper
• Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: Effects on insulin-like growth factor I signaling (Molecular Cancer Therapeutics (2007) 6, (667-674))

  2008cited by this paper
• Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling

  2007cited by this paper
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  2007cited by this paper
• Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles

  2007cited by this paper
• Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models

  2007cited by this paper
• Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

  2006cited by this paper
• Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.

  2006cited by this paper
• Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

  2006cited by this paper
• Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

  2005cited by this paper
• Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells

  2005cited by this paper
• Potential Prognostic Significance of p185HER2 Overexpression with Loss of PTEN Expression in Gastric Carcinomas

  2005cited by this paper
• [Combination chemotherapy of TS-1 and docetaxel on advanced and recurrent gastric cancer].

  2004cited by this paper
• Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines.

  2004cited by this paper
• Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib.

  2004cited by this paper
• Molecular mechanisms underlying IGF‐I‐induced attenuation of the growth‐inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells

  2004cited by this paper
• The Mitogenic Action of Insulin-like Growth Factor I in Normal Human Mammary Epithelial Cells Requires the Epidermal Growth Factor Receptor Tyrosine Kinase*

  2004cited by this paper
• Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers

  2003cited by this paper
• The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature

  2003cited by this paper
• Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.

  2002cited by this paper
• Status of c‐erbB‐2 in gastric adenocarcinoma: A comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme‐linked immuno‐sorbent assay

  2002cited by this paper
• Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer.

  2002cited by this paper
• Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.

  2002cited by this paper
• Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5′-dFUrd in human breast cancer models

  2002cited by this paper
• The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

  2001cited by this paper
• Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

  2001cited by this paper
• Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling.

  2001cited by this paper
• Phosphatidylinositol-3 kinase dependent pathways: the role in control of cell growth, survival, and malignant transformation.

  2000cited by this paper
• Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.

  2000cited by this paper
• Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity.

  1999cited by this paper
• Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

  1999cited by this paper
• Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene.

  1999cited by this paper
• Physical Interaction between Epidermal Growth Factor Receptor and DNA-dependent Protein Kinase in Mammalian Cells*

  1998cited by this paper
• Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase.

  1998cited by this paper
• c-erbB-2 expression is predictive for lymphatic spread of clinical gastric carcinoma.

  1997cited by this paper
• Establishment and characterization of human gastric carcinoma cell lines

  1997cited by this paper
• Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.

  1994cited by this paper
• Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity.

  1994cited by this paper
• p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair.

  1994cited by this paper
• Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer.

  1991cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

  1989cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper

• A literature review of recent advances in gastric cancer treatment: exploring the cross-talk between targeted therapies

  2025cites this paper
• Concept of Targeted Drug Conjugate and Its Application in Reversing Drug Resistance.

  2025cites this paper
• HER2-Positive Gastric Cancer and Antibody Treatment: State of the Art and Future Developments

  2024cites this paper
• Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications

  2023cites this paper
• Structure–Activity Relationship Studies Based on Quinazoline Derivatives as EGFR Kinase Inhibitors (2017–Present)

  2023cites this paper
• Pan-HER Tyrosine Kinase Inhibitor Pyrotinib Enhances Radiosensitivity via ERK1/2 Pathway in HER2-Positive Gastric Cancer

  2022cites this paper
• Current treatments and outlook in adenocarcinoma of the esophagogastric junction: a narrative review

  2022cites this paper
• A ligand-receptor interactome platform for discovery of pain mechanisms and therapeutic targets

  2021cites this paper
• Evaluation of Near-infrared Fluorescence-conjugated Peptides for Visualization of Human Epidermal Receptor 2-overexpressed Gastric Cancer

  2021cites this paper
• Quantitative Proteomics of the Cancer Cell Line Encyclopedia.

  2020cites this paper
• Comprehensive Molecular Characterization of Adenocarcinoma of the Gastroesophageal Junction Between Esophageal and Gastric Adenocarcinomas

  2020cites this paper
• Comprehensive Molecular Characterization of Adenocarcinoma of the Gastroesophageal Junction Between Esophageal and ocarcinomas

  2020cites this paper
• Sensitive Photoacoustic/Magnetic Resonance Dual Imaging Probe for Detection of Malignant Tumors.

  2020cites this paper
• Preclinical evaluation and molecular imaging of HER family dynamics to guide cancer therapy

  2019cites this paper
• Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS/RAF/MEK/ERK pathway: phase Ib study

  2019cites this paper
• Anticancer Drug Response Prediction in Cell Lines Using Weighted Graph Regularized Matrix Factorization

  2019cites this paper
• The role of Her2-Nrf2 axis in induction of oxaliplatin resistance in colon cancer cells.

  2018cites this paper
• Lapatinib.

  2018cites this paper
• Tissu adipeux et résistance tumorale aux thérapies ciblées

  2018cites this paper
• Design and synthesis of novel triazolo-lapatinib hybrids as inhibitors of breast cancer cells

  2018cites this paper
• Anti-tumour effect of lapatinib in canine transitional cell carcinoma cell lines.

  2018cites this paper
• Epidermal Growth Factor Receptor activation promotes ADA3 acetylation through the AKT-p300 pathway

  2017cites this paper
• Clinicopathologic and prognostic significance of human epidermal growth factor receptor in patients with gastric cancer: An updated meta-analysis

  2017cites this paper
• 89Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment

  2017cites this paper
• FOXO1 Suppression is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells Through MET Upregulation

  2017cites this paper
• Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?

  2017cites this paper
• A Phase II Study with Lead‐In Safety Cohort of 5‐Fluorouracil, Oxaliplatin, and Lapatinib in Combination with Radiation Therapy as Neoadjuvant Treatment for Patients with Localized HER2‐Positive Esophagogastric Adenocarcinomas

  2017cites this paper
• Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms

  2016cites this paper
• ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy.

  2016cites this paper
• An update on the current pharmacotherapy for endometrial cancer

  2016cites this paper
• Substitution of Heavy Complementarity Determining Region 3 (CDR-H3) Residues Can Synergistically Enhance Functional Activity of Antibody and Its Binding Affinity to HER2 Antigen

  2016influential citation
• Therapeutic implication of HER2 in advanced biliary tract cancer

  2016cites this paper
• Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer.

  2016cites this paper
• Gastric Carcinoma at the Era of Targeted Therapies.

  2016cites this paper
• Novel Targeted Therapy for Advanced Gastric Cancer

  2015cites this paper
• Evaluation of Lapatinib Powder-Entrapped Biodegradable Polymeric Microstructures Fabricated by X-Ray Lithography for a Targeted and Sustained Drug Delivery System

  2015cites this paper
• Future Directions and New Targets in Endometrial Cancer

  2015cites this paper
• miR‐1470 mediates lapatinib induced p27 upregulation by targeting c‐jun

  2015cites this paper
• Treatment for unresectable gastric cancer

  2015cites this paper
• Gastric cancer: The times they are a-changin'.

  2015cites this paper
• Investigational therapies targeting the ErbB family in oesophagogastric cancer

  2014cites this paper
• Testican-1-mediated epithelial–mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer

  2014cites this paper
• The role of epidermal growth factor receptor in prognosis and treatment of gastric cancer

  2014cites this paper
• The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey

  2014cites this paper
• RETRACTED ARTICLE: Inhibition of epidermal growth factor receptor signaling prohibits metastasis of gastric cancer via downregulation of MMP7 and MMP13

  2014cites this paper
• Targeted Therapy in Uterine Serous Carcinoma: An Aggressive Variant of Endometrial Cancer

  2014cites this paper
• MiRNA-34a inhibits EGFR-signaling-dependent MMP7 activation in gastric cancer

  2014cites this paper
• Role of human epidermal growth factor receptor 2 in gastric cancer: biological and pharmacological aspects.

  2014cites this paper
• Micelle-based activatable probe for in vivo near-infrared optical imaging of cancer biomolecules.

  2014cites this paper
• Unraveling trastuzumab and lapatinib inefficiency in gastric cancer: Future steps (Review).

  2014cites this paper
• Correction: Lapatinib-Binding Protein Kinases in the African Trypanosome: Identification of Cellular Targets for Kinase-Directed Chemical Scaffolds

  2014cites this paper
• AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel.

  2014cites this paper
• Predicting Probable Ligands to Inhibit HER2-EGFR in Gastric Cancer

  2014cites this paper
• Lapatinib.

  2014cites this paper
• Lapatinib induces p27Kip1-dependent G₁ arrest through both transcriptional and post-translational mechanisms

  2013cites this paper
• Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line

  2013cites this paper
• Lapatinib sensitivities of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines

  2013cites this paper
• Prognostic value of epidermal growth factor receptor in patients with gastric cancer: a meta-analysis.

  2013cites this paper
• Heregulin induces resistance to lapatinib‐mediated growth inhibition of HER2‐amplified cancer cells

  2013cites this paper
• Targeted therapy for gastric cancer—current status

  2013cites this paper
• Epidermal growth factor receptor (EGFR)-targeted therapies in esophagogastric cancer.

  2013cites this paper
• Cbl-b Enhances Sensitivity to 5-Fluorouracil via EGFR- and Mitochondria-Mediated Pathways in Gastric Cancer Cells

  2013cites this paper
• Gastric cancer—molecular and clinical dimensions

  2013cites this paper
• Molecular Targeted Agents for Gastric Cancer: A Step Forward Towards Personalized Therapy

  2013cites this paper
• Indications et gestion des effets secondaires

  2013cites this paper
• Novel Functions of Cetuximab in EGFR-targeted Therapy: Radiosensitization, Glycolysis Inhibition, and Cellular Redox Status Regulation

  2013cites this paper
• The role of E-cadherin in EGFR signal transduction and EGFR-inhibitory treatment in gastric cancer

  2013cites this paper
• HER2 Expression Beyond Breast Cancer: Therapeutic Implications for Gynecologic Malignancies

  2013cites this paper
• Is there an Increased Risk of Central Nervous System Metastasis in Caseswith Gastric Cancer Showing Her2 Expression and Treated by Trastuzumab

  2013cites this paper
• Imatinib radiosensitizes bladder cancer by targeting homologous recombination.

  2013cites this paper
• Gastric cancer: past accomplishments, present approaches and future aspirations

  2013cites this paper
• Lapatinib-Binding Protein Kinases in the African Trypanosome: Identification of Cellular Targets for Kinase-Directed Chemical Scaffolds

  2013cites this paper
• Advanced HER2-positive gastric cancer: current and future targeted therapies.

  2013cites this paper
• MicroRNA and HER2-overexpressing Cancer

  2013cites this paper
• Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer

  2012cites this paper
• The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines

  2012cites this paper
• Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells

  2012cites this paper
• The prognostic significance of HER2 positivity for advanced gastric cancer patients undergoing first-line modified FOLFOX-6 regimen.

  2012cites this paper
• Preclinical Development Evaluation of the Antitumor Effects and Mechanisms of PF 00299804 , a Pan-HER Inhibitor , Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer

  2012cites this paper
• Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors

  2012cites this paper
• Molecular targeted agents for gastric and gastroesophageal junction cancer

  2012cites this paper
• A-62176, a potent topoisomerase inhibitor, inhibits the expression of human epidermal growth factor receptor 2.

  2012cites this paper
• Combined effects of lapatinib and cisplatin on colony formation of head and neck squamous cell carcinoma.

  2012cites this paper
• Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: from pathology to treatment.

  2012cites this paper
• The anti-EGFR antibody cetuximab sensitizes human head and neck squamous cell carcinoma cells to radiation in part through inhibiting radiation-induced upregulation of HIF-1α.

  2012cites this paper
• Mechanisms of resistance to lapatinib in HER2 positive breast cancer

  2012cites this paper
• Relevance of MET activation and genetic alterations of KRAS and E-cadherin for cetuximab sensitivity of gastric cancer cell lines

  2012cites this paper
• MET Activation Mediates Resistance to Lapatinib Inhibition of HER2-Amplified Gastric Cancer Cells

  2012cites this paper
• Array-based pharmacogenomics of molecular-targeted therapies in oncology

  2012cites this paper
• Preclinical Development MET Activation Mediates Resistance to Lapatinib Inhibition of HER 2-Ampli fi ed Gastric Cancer Cells

  2012cites this paper
• The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.

  2011cites this paper
• Trastuzumab plus Chemotherapy in Gastric Cancer Overexpressing HER-2 and EGFR: A Case Report

  2011cites this paper
• Clinicopathologic Characteristics of Patients With Stage III/IV (M0) Advanced Gastric Cancer, According to HER2 Status Assessed by Immunohistochemistry and Fluorescence In Situ Hybridization

  2011cites this paper
• Antitumor activity of NVP‐AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins

  2011cites this paper
• Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer

  2011cites this paper
• Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer

  2011influential citation
• Evolving standards of care in advanced gastric cancer.

  2011cites this paper
• Targeted Therapies for Gastric Cancer

  2011cites this paper
• Targeted therapies in the treatment of gastric cancer

  2011cites this paper
• Targeting the human EGFR family in esophagogastric cancer

  2011cites this paper